55 completed, 24 unknown, 5 terminated, 4 active not recruiting. 44 Phase 3, 35 Phase 2, 14 Phase 1, 2 Not applicable.
Follow Epirubicin Hydrochloride: new trials by email Literature Review of Epirubicin Hydrochloride trials Research Report on Epirubicin Hydrochloride
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003) Pembrolizumab, Paclitaxel, Carboplatin - Early Triple Negative Breast Cancer | Phase 2 | Withdrawn | Merck Sharp & Dohme LLC | 2025-03-26 | 2026-02-19 | |
| Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) Patritumab deruxtecan, Pembrolizumab, Paclitaxel - Breast Neoplasms, Breast Cancer | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 372 | 2025-03-20 | 2026-09-10 |
| Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma Idarubicin Hydrochloride for Injection, Epirubicin - Hepatocellular Carcinoma | Not applicable | Unknown | Zhejiang Cancer Hospital | 186 | 2021-10-01 | 2021-09-22 |
| A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients APL-1202, Epirubicin Hydrochloride - Non-muscle Invasive Bladder Cancer | Phase 3 | Unknown | Jiangsu Yahong Meditech Co., Ltd aka Asieris | 800 | 2021-09-29 | 2022-02-22 |
| Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer Epirubicin, Cyclophosphamid, Docetaxel - HER2-negative Breast Cancer, Neoadjuvant Chemotherapy | Phase 2 / Phase 3 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 260 | 2020-09-20 | 2021-08-12 |
| Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients epirubicin hydrochloride, Cyclophosphamide, Albumin bound paclitaxel - Triple Negative Breast Cancer | Phase 2 | Unknown | Fudan University | 70 | 2020-06-09 | 2024-05-21 |
| VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma Bortezomib, Rituximab, Epirubicin - Marginal Zone Lymphoma | Phase 2 | Completed | Henan Cancer Hospital | 26 | 2020-04-22 | 2026-04-09 |
| R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma Rituximab, Lenalidomide, Cyclophosphamide - Diffuse Large B Cell Lymphoma | Phase 2 | Completed | Henan Cancer Hospital | 60 | 2020-01-05 | 2025-11-19 |
| Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma Camrelizumab, Epirubicin, Vincristine - Classical Hodgkin Lymphoma | Phase 2 | Active not recruiting | Henan Cancer Hospital | 60 | 2019-08-26 | 2026-02-02 |
| Breast Cancer Treatment Based on Organ-like Culture Trastuzumab, Doxorubicin Hydrochloride, Epirubicin hydrochloride - Breast Cancer Organoids | Unknown | Xijing Hospital | 300 | 2019-01-02 | 2019-04-24 | |
| Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer pegylated liposomal doxorubicin hydrochloride, epirubicin hydrochloride, carboplatin - Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Active not recruiting | Rutgers, The State University of New Jersey | 62 | 2015-02-25 | 2023-03-29 |
| Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma Epirubicin Hydrochloride, External Beam Radiation Therapy, Ifosfamide - Pleomorphic Rhabdomyosarcoma, Stage IIB Adult Soft Tissue Sarcoma AJCC v7 | Phase 2 | Completed | OHSU Knight Cancer Institute | 20 | 2013-12-03 | 2022-03-21 |
| Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer Dinaciclib, Epirubicin Hydrochloride, Laboratory Biomarker Analysis - Estrogen Receptor Negative, HER2/Neu Negative | Phase 1 | Completed | National Cancer Institute (NCI) | 40 | 2012-08-21 | 2018-03-30 |
| Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer Bevacizumab, Cyclophosphamide, epirubicin hydrochloride - Inflammatory Breast Cancer | Phase 1 | Unknown | Association Tunisienne de lutte Contre le Cancer | 30 | 2011-03-01 | 2013-06-19 |
| Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer capecitabine, cisplatin, epirubicin hydrochloride - Adenocarcinoma of the Gastroesophageal Junction, Gastric Cancer | Phase 2 | Terminated | European Organisation for Research and Treatment of Cancer - EORTC | 29 | 2010-12-01 | 2016-10-12 |
| Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer BCG solution, recombinant interferon alfa, epirubicin hydrochloride - Bladder Cancer | Phase 3 | Unknown | Cancer Research Campaign Clinical Trials Centre | 242 | 2009-10-01 | 2013-08-12 |
| Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors epirubicin hydrochloride, panobinostat, gene expression analysis - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | University of California, San Francisco | 40 | 2009-09-13 | 2017-03-24 |
| Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer bevacizumab, cyclophosphamide, docetaxel - Breast Cancer, Cardiac Toxicity | Phase 3 | Unknown | Cambridge University Hospitals NHS Foundation Trust | 800 | 2009-04-01 | 2010-03-25 |
| Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma epirubicin hydrochloride, ifosfamide, sorafenib tosylate - Sarcoma | Phase 1 | Completed | OHSU Knight Cancer Institute | 18 | 2009-02-01 | 2018-09-07 |
| Efficacy and Tolerance Study of Bevacizumab in Her2- Inflammatory Breast Cancer Patients bevacizumab, cyclophosphamide, docetaxel - Breast Cancer | Phase 2 | Completed | UNICANCER | 100 | 2009-01-01 | 2019-10-22 |
Showing 20 of 91. Sign in to see all of them.
Breast Neoplasms (49) · Inflammatory Breast Neoplasms (9) · Stomach Neoplasms (8) · Breast Neoplasms, Male (5) · Carcinoma, Hepatocellular (5) · Esophageal Neoplasms (4) · Liver Neoplasms (4) · Lymphoma (4) · Sarcoma (4) · Triple Negative Breast Neoplasms (4) · Adenocarcinoma Of Esophagus (3) · Ovarian Neoplasms (3) · Bile Duct Neoplasms (2) · Desmoplastic Small Round Cell Tumor (2) · Fibrosarcoma (2)
UNICANCER (8) · European Organisation for Research and Treatment of Cancer - EORTC (4) · NCIC Clinical Trials Group (4) · Henan Cancer Hospital (3) · Medical Research Council (3) · Alliance for Clinical Trials in Oncology (2) · Cambridge University Hospitals NHS Foundation Trust (2) · Cancer Research Campaign Clinical Trials Centre (2) · Cancer Trials Ireland (2) · Case Comprehensive Cancer Center (2) · ETOP IBCSG Partners Foundation (2) · IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy (2) · IRCCS San Raffaele (2) · Institute of Cancer Research, United Kingdom (2) · Merck Sharp & Dohme LLC (2)
United States (25) · United Kingdom (22) · France (14) · Italy (10) · China (8) · Belgium (7) · Canada (7) · Switzerland (7) · Germany (5) · Portugal (5) · Ireland (4) · Netherlands (4) · Spain (4) · Poland (3) · Slovenia (3)
Helena Earl, MBBS, PhD, FRCP (3) · Yanyan Liu, M.D. Ph.D (3) · Gunnar B. Kristensen, MD, PhD (2) · John Crown, MD (2) · Maureen E. Trudeau, BSc, MA, MD, FRCPC (2) · Michele Reni, MD (2) · Pierre Biron, MD (2) · R. Charles Coombes, MD, MRCP, FRCP, PhD, FMedSci (2) · Aman Buzdar (1) · Andrew S. Kraft, MD (1) · Andrew X. Zhu, MD, PhD (1) · Annabel B.M. Foot (1) · Anne Lennard (1) · Arnaud Roth (1)
PMID 10076722, PMID 10458221, PMID 11181777, PMID 14656276, PMID 15967833, PMID 16293863, PMID 16421418, PMID 16822992, PMID 17664469, PMID 18024211, PMID 18037940, PMID 18224661, PMID 18768436, PMID 18797468, PMID 18952561, PMID 19468030, PMID 19771508, PMID 19917839, PMID 20308670, PMID 20308671, PMID 20338746, PMID 20623180, PMID 20667781, PMID 21570352, PMID 21771987, PMID 22508812, PMID 22539562, PMID 22665534, PMID 23332384, PMID 24239210, PMID 24273046, PMID 24360787, PMID 24618153, PMID 24915873, PMID 25740286, PMID 25897014, PMID 25947565, PMID 25975632, PMID 26063893, PMID 26101239, PMID 26206258, PMID 26208483, PMID 26306520, PMID 26543765, PMID 26715442, PMID 26720025, PMID 26852132, PMID 26882907, PMID 26903311, PMID 27032301
P30CA072720 (2), U10CA012027 (2), 2005 (1), 2008 (1), 2009 (1), P30CA008748 (1), P30CA015083 (1), P30CA016672 (1), P30CA036727 (1), P30CA043703 (1), P30CA051008 (1), P30CA069533 (1), R01CA152228 (1), U01CA062461 (1), U10CA031946 (1)